Mobile Health Innovative Solutions v. Heartify: Voluntary Dismissal in 43 Days
Mobile Health Innovative Solutions, LLC filed a patent infringement suit against Heartify, LLC in Massachusetts, asserting US11468984B2 covering a Health Data Platform. The case ended by voluntary dismissal in just 43 days — before Heartify served any answer or motion for summary judgment.
A swift exit: Mobile Health drops infringement suit against Heartify
On October 22, 2024, Mobile Health Innovative Solutions, LLC filed an infringement action against Heartify, LLC in the U.S. District Court for the District of Massachusetts (Case No. 1:24-cv-12671), before Judge William G. Young. The asserted patent, US11468984B2, relates to a Health Data Platform — technology covering digital health data collection, management, or integration. Heartify, a competing entity in the digital health space, was the sole named defendant.
The case closed on December 4, 2024 — just 43 days after filing — when plaintiff Mobile Health Innovative Solutions submitted a Notice of Voluntary Dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). The notice states that defendant Heartify had not yet served an answer or a motion for summary judgment at the time of dismissal, satisfying the procedural condition for unilateral voluntary dismissal. The public record does not specify whether the dismissal was with or without prejudice.
A 43-day lifecycle is strikingly short even for cases that settle early, suggesting the parties may have reached a rapid accommodation — or that plaintiff reassessed its enforcement position very quickly after filing. Because the dismissal was filed under Rule 41(a)(1)(A)(i) and the basis of termination is listed as ‘Voluntary dismissal’ without further qualification, the public record leaves the prejudice question ambiguous. No fees, costs, or merits rulings were recorded.
Filing to Voluntary dismissal in 43 days
43 days — well below the typical district court lifecycle of 2–3 years
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): the plaintiff’s unilateral exit right
Federal Rule of Civil Procedure 41(a)(1)(A)(i) allows a plaintiff to dismiss a case without a court order if the defendant has not yet served an answer or a motion for summary judgment. Mobile Health exercised this right here, meaning the dismissal required no judicial approval and carries no merits ruling. The court made no finding on infringement, validity, or any substantive issue relating to US11468984B2.
No merits adjudicationThe prejudice question: public record is silent
A dismissal ‘with prejudice’ bars the plaintiff from re-filing the same claim — it functions as a final judgment on the merits. A dismissal ‘without prejudice’ preserves the plaintiff’s right to refile. The basis of termination here is recorded simply as ‘Voluntary dismissal,’ and the verdict notice text does not resolve this distinction with certainty. Parties and counsel should not assume re-filing is foreclosed, but equally should not assume it is guaranteed without independent verification of the filed notice.
Prejudice status unconfirmedHeartify exits without an adverse ruling — but risk may persist
Heartify, LLC faced no adjudication of infringement and no damages award. Because Heartify had not yet answered, the case ended before any substantive litigation burden was incurred. However, if the dismissal is without prejudice, Mobile Health could potentially refile the same claims relating to US11468984B2. Heartify and its counsel would be prudent to monitor Mobile Health’s enforcement activity and assess the strength of any non-infringement or invalidity positions.
No adverse findingUS11468984B2 remains in play for the digital health sector
The voluntary dismissal resolves nothing about the validity or scope of US11468984B2. For competitors and investors in the Health Data Platform space, the patent continues to represent an active enforcement risk. The speed of this dismissal — 43 days — suggests the dispute may have concluded through negotiation, licensing, or a reassessment of claim scope, but no public record confirms any such arrangement. Companies operating in adjacent digital health data management segments should conduct FTO analysis against this patent.
Patent still enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Mobile Health Innovative Solutions, LLC | Company | Digital health technology company — holder of US11468984B2 (Health Data Platform)Search in Eureka ↗ |
| Defendant | Heartify, LLC | Company | Heartify, LLC — digital health platform operator named in infringement actionSearch in Eureka ↗ |
| Plaintiff counsel | Brendan M. Shortell | Attorney | Counsel for Mobile Health Innovative Solutions, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Lambert Shortell & Connaughton | Law Firm | Representing Mobile Health Innovative Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Aaron S. Jacobs | Attorney | Counsel for Heartify, LLCSearch in Eureka ↗ |
| Defendant counsel | Cameron D. Panepinto | Attorney | Counsel for Heartify, LLCSearch in Eureka ↗ |
| Defendant law firm | Prince Lobel Tye LLP | Law Firm | Representing Heartify, LLCSearch in Eureka ↗ |
| Presiding judge | Judge William G. Young | Judge | Massachusetts District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i), confirming that Heartify had not served an answer or summary judgment motion — a procedural prerequisite for unilateral plaintiff dismissal. No court order was required, and Judge Young made no substantive findings. The notice text does not expressly characterise the dismissal as with or without prejudice, meaning its preclusive effect is not definitively resolved on the face of the public record alone.
US11468984B2 — Health Data Platform technology
US11468984B2, filed under application number US16/850984, covers technology relating to a Health Data Platform. The patent sits within the digital health domain, which broadly encompasses systems for collecting, processing, and managing patient or consumer health data. The ‘B2’ designation indicates a granted utility patent with a correction or republication. The application date context suggests filing during a period of rapid expansion in digital health infrastructure, coinciding with increased regulatory and commercial attention to health data interoperability.
In the competitive digital health sector, platform-level patents covering data integration or management architectures can command significant licensing leverage, particularly as health data interoperability requirements (e.g., under 21st Century Cures Act mandates) push more companies into overlapping technical territory. US11468984B2 has not been tested on validity or claim scope in adversarial litigation proceedings, which means its enforceability profile remains uncertain — but also that potential defendants cannot rely on any prior adjudication to reduce risk.
Should your product team run an FTO against US11468984B2?
Any company developing, licensing, or commercialising a Health Data Platform — including patient data aggregation tools, health record integration APIs, or connected wellness data systems — should treat US11468984B2 as a relevant FTO consideration. The patent has been actively asserted in litigation, and the voluntary dismissal leaves its enforceability intact. R&D teams building in adjacent spaces, particularly in Massachusetts or targeting US markets, face direct exposure if their architecture overlaps with the patent’s independent claims.
PatSnap Eureka’s FTO Search Agent allows product and IP teams to map US11468984B2 claim elements against their own system architectures, identify prior art that may support invalidity arguments, and surface related patents in the Mobile Health Innovative Solutions portfolio. Running a structured FTO now — before any refiling or broader enforcement campaign — is materially less costly than responding to litigation. Eureka’s claim chart generation and prosecution history analysis tools are designed for exactly this pre-launch risk assessment.
Run a freedom-to-operate analysis on US11468984B2 to assess your product’s exposure
Run FTO in Eureka →Similar Health Data Platform patent cases in Massachusetts and beyond
Cases involving Health Data Platform patent assertions in the District of Massachusetts and comparable digital health infringement actions in US federal courts.
What this case signals for the digital health IP landscape
A 43-day lifecycle and voluntary dismissal before any answer suggest this case warrants close monitoring by digital health platform operators.
Early voluntary dismissals often precede licensing or refiling — track US11468984B2
When plaintiffs dismiss under Rule 41(a)(1)(A)(i) this quickly, it typically signals one of two outcomes: a private resolution (e.g., licensing agreement) or a tactical reassessment of claims. Neither outcome is public here. Digital health companies should monitor Mobile Health’s future enforcement activity against this patent family.
No merits ruling means US11468984B2 validity is untested in litigation
No court has assessed the scope or validity of US11468984B2 in adversarial proceedings. For companies operating Health Data Platform products, this patent remains a genuine litigation risk. An FTO analysis is warranted before launching or scaling products that overlap with its claim landscape.
Mobile v Heartify — key questions answered
Mobile Health Innovative Solutions, LLC filed a patent infringement action against Heartify, LLC in the District of Massachusetts on October 22, 2024, asserting US11468984B2. The case was voluntarily dismissed on December 4, 2024, after just 43 days, before Heartify served any answer or summary judgment motion.
Rule 41(a)(1)(A)(i) permits a plaintiff to dismiss unilaterally before the defendant has served an answer or summary judgment motion. No court approval is needed and no merits ruling is issued. For Heartify, this means no adverse finding on infringement — but if the dismissal is without prejudice, re-filing remains a possibility for the plaintiff.
The basis of termination is recorded as ‘Voluntary dismissal’ without explicit prejudice qualification in the available public record. The verdict notice text invokes Rule 41(a)(1)(A)(i) but does not conclusively resolve the with/without prejudice question on its face. Independent verification of the filed notice is recommended for parties assessing re-filing risk.
US11468984B2 (application US16/850984) covers a Health Data Platform — technology relating to the collection, management, or integration of health data. Companies developing patient data aggregation systems, health record APIs, or connected wellness platforms in the US market face potential exposure and should conduct FTO analysis against this patent’s claims.
The 43-day duration is strikingly short and may suggest the parties reached a private resolution — such as a licensing arrangement or covenant not to sue — or that plaintiff reassessed the strength of its infringement position. No settlement terms or fee arrangements were publicly recorded. The speed of dismissal before any substantive litigation activity is consistent with early-stage negotiation outcomes, though the public record does not confirm any such arrangement.
PatSnap Eureka searches patents and litigation data to answer instantly.